About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Budesonide / Formoterol in Treatment of Exacerbations of COPD

NCT00239278·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

40–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

smoking-induced COPD according to ATS criteria
FEV1 \<85% of predicted at enrolment and \<70% of predicted but \> 0.7 Liter at Exacerbation
FEV1/IVC ratio \<88% of predicted for men and \<89% for women

You may not be if

history of asthma
known hypersensitivity to the study drugs
serious concomitant diseases
pregnancy or lactating
abnormal Chest X-ray or blood gasses

The record

StatusCompleted

PhasePhase 2

Taking part120

StartedJan 2001

UpdatedJan 24, 2011

Conditions

Chronic Obstructive Pulmonary Disease

Where1

Research Site
Groningen, Netherlands

Clareo Health | Budesonide / Formoterol in Treatment of Exacerbations of COPD